Manufacturer record
Daxin Pharmaceuticals Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
9 batches manufactured by Daxin Pharmaceuticals Pvt. Ltd (Himachal Pradesh) were declared Not of Standard Quality between December 2023 and September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: 35, Povidone-Iodine Solution IP 5% w/v (exp Jul 2027). DTL, Bengaluru, Karnataka (state lab) found it not of standard quality: Assay for Available-Iodine. Listed in the September 2026 alert.
Records by type
9 records linked to Daxin Pharmaceuticals Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Povidone-Iodine Solution IP 5% w/v | Batch 35Mfg Aug 2025 · Exp Jul 2027 | Assay for Available-IodineAssay | DTL, Bengaluru, KarnatakaState lab | Sep 2026 |
| Amoxycillin Capsuels IP 250 mg | Batch DVC250083Mfg Oct 2025 · Exp Sep 2027 | The sample does not conform to IP in respect of Assay and Dissolution of AmoxycillinAssay | LUCKNOW LABState lab | Aug 2026 |
| Cefixime Dispersible Tablets IP | Batch DB240368Mfg Dec 2024 · Exp Nov 2026 | The sample does not conform to I.P. w.r.to the tests for AssayAssay | SDTL,GuwahatiState lab | Jul 2026 |
| Cefem -200 Tablets, Cefixime with Lactic Acid Bacillus tablets | Batch DB240126Mfg Apr 2024 · Exp Mar 2026 | NOT OF STANDARD QUALITY 1. Thirteen Individual weights deviated from the average weight 636.0 mg i.e 6 tablets deviated by less than 5 percent and 7 tablets deviated by more than 5 percent. Hence the sample does not complies the test Uniformity of weight. 2. Assay of Cefixime does not complies. Hence the sample is of NOT OF STANDARD QUALITYAssay | State Lab Drugs Control Laboratory, TelanganaState lab | Oct 2024 |
| Cefoperazone & Sulbactam For Injection (Todaycef 1.5 G) | Batch D0481Mfg Nov 2023 · Exp Oct 2025 | Clarity of Solution, Particulate matter and AssayAssay | CDL KolkataCDSCO lab | Aug 2024 |
| Cefixime & Ofloxacin Tablets (CEFIKAM OF 200) | Batch DB230057Mfg Feb 2023 · Exp Jan 2025 | Assay of Cefixime Trihydrate & Assay OfloxacinAssay | CDL KolkataCDSCO lab | Jun 2024 |
| CefuroximeAxetil Tablets IP | Batch DB23030 4Mfg Dec 2023 · Exp Nov 2025 | The sample does not conforms to claim as per IP 2022in respect to the Test of Dissolution of Cefuroxime Axetil equivalent to CefuroximeDissolution | CDL KolkataCDSCO lab | May 2024 |
| Cefixime & Ofloxacin Tablets | Batch DB23005 7Mfg Feb 2023 · Exp Jan 2025 | The sample does not conforms to claim as per Schedule V of Drugs & Cosmetics Act with respect to the Assay of Cefixime Trihydrate eq. to anhydrous Cefixime and Assay of OfloxacinAssay | CDL KolkataCDSCO lab | May 2024 |
| Paracetamol Tablets IP 650mg. (DAXIPAR-650 Tablets) | Batch DPT22863Mfg Sep 2022 · Exp Aug 2024 | DissolutionDissolution | RDTL GuwahatiState lab | Dec 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.